Treatment with IMMU-132 (sacituzumab govitecan) elicited an objective response rate (ORR) of 34 percent in patients with heavily pretreated metastatic triple-negative breast cancer, according to updated findings from a phase 2 study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). Apr 26, 2019 · At first glance, it would seem triple-positive breast cancer would offer the best prognosis, followed by tumors that are estrogen-receptor-positive or HER2-positive, and triple-negative tumors having the worst outcomes. However, that doesn't appear to be the case.
Triple-negative breast cancer is the term used to describe breast cancers that lack estrogen- and progesterone-receptor expression and do not overexpress human epidermal growth factor receptor 2 Cited by: 176. Mar 20, 2017 · The antibody-drug conjugate sacituzumab govitecan (IMMU-132) demonstrated meaningful clinical benefit in heavily-pretreated patients with metastatic triple-negative breast cancer (TNBC). These findings were published in the Journal of Clinical Oncology. The single-arm phase 2 study included 69 patients with TNBC, according to a press release.
Jun 03, 2019 · SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019. Mar 27, 2014 · Triple-negative breast cancer (TNBC) is characterized by unique aggressive behavior and lack of targeted therapies. Among the various molecular subtypes of breast cancer, it was observed that TNBCs express elevated levels of sphingosine kinase 1 (SPHK1) compared to Cited by: 34.
Dec 11, 2014 · Keytruda Produces Antitumor Responses in Triple-Negative Breast Cancer The PD-1 inhibitor Keytruda (pembrolizumab) has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC). Apr 28, 2015 · Triple-negative breast cancer is a heterogeneous disease characterized by poor clinical outcomes and a shortage of targeted treatment options. To discover molecular features of triple-negative breast cancer, we performed quantitative proteomics analysis of Cited by: 116.
Apr 18, 2017 · Out of the breast cancer subtypes, triple-negative breast cancer (TNBC) has the poorest prognosis without effective targeted therapies. Metformin, a first-line drug for type 2 diabetes mellitus Cited by: 20. Apr 15, 2019 · Moreover, because patients with triple-negative breast cancer who achieve a pathologic complete response are more likely to be breast cancer–free for the rest of their lives, the long-term impact of such an improvement in pathological complete response rates is promising, potentially clinically significant, and warrants confirmation.Author: Heather McArthur.